CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
NCT07443137
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Large-cell Lymphoma
Interventions
BIOLOGICAL:
Rapcabtagene autoleucel (YTB323)
Sponsor
Stanford University
Collaborators
[object Object]